Colivelin is a potent synthetic peptide activator of STAT3 that has neuroprotective activity. It protects approximately 50 and 100% of mouse primary cortical neurons from cell death induced by amyloid β (1-43) (Aβ43) when used at concentrations of 10 and 100 fM, respectively. Colivelin protects against cell death induced by V642I-APP in a CaM kinase IV (CaMKIV) and STAT3-dependent manner. It increases STAT3 phosphorylation in vitro and in vivo, an effect that correlates with improvements in working memory. Colivelin (10 pmol every six days) rescues deficits in spatial working memory in a mouse model of Alzheimer’s disease induced by intracerebroventricular injection of Aβ25-35. It also improves motor performance and prolongs survival in a mouse model of amyotrophic lateral sclerosis (ALS).
Colivelin is a peptide that offers neuroprotective effects against Alzheimer''s Disease (AD). It is also an activator of STAT3, a transcription factor involved with the JAK2/STAT3 pathway. Aberration in this pathway is linked to the pathogenesis of AD. Neuroprotective product.
Colivelin is a humanized peptide with neuroprotective effects that has a strong ability to fight against Aβ deposition, neuronal apoptosis, and synaptic plasticity defects in neurodegenerative diseases. Its neuroprotective pathway can be related to activating the STAT3 signaling pathway by inhibiting axonal damage and neuronal death in brain tissue. In addition, Colivelin may also occur through Ca2+/calmodulin-dependent protein kinase IV mediated by ADNF.
